Free Trial
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:CRIS

Curis Q3 2026 Earnings Date & Estimates

Curis logo
$0.62 -0.03 (-4.40%)
Closing price 03:59 PM Eastern
Extended Trading
$0.62 +0.00 (+0.16%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Curis is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. The conference call is scheduled for 4:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call
4:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Curis in Q3 2026

Curis is expected to post earnings of -$2.29 per share on revenue of $1.00 million. In the same quarter a year earlier Curis reported -$9.80 per share on revenue of $3.18 million. Curis last reported on August 14, 2026, posting -$4.02 per share and beating the -$6.95 consensus estimate. Curis has beaten the consensus EPS estimate in 4 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$2.29
Expected Revenue
$1.00 million
Prior-Year EPS
-$9.80
Prior-Year Revenue
$3.18 million
Expected Revenue Growth
-68.5%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$4.02 (Beat by +$2.93)
EPS Beat Rate
4 of last 8 quarters

Prepare for the Q3 2026 Call

Curis Q3 2026 Earnings FAQ

Curis (NASDAQ:CRIS) is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Curis' Q3 2026 earnings conference call is scheduled for Thursday, November 5, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Curis to post earnings of -$2.29 per share for Q3 2026.

The consensus revenue estimate for Curis is $1.00 million for Q3 2026.

Curis Earnings Headlines

Reviewing Curis (NASDAQ:CRIS) & Verastem (NASDAQ:VSTM)
October 7, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31095566
Analysts Are Bullish on These NA Stocks: Curis (CRIS), Canadian National Railway (CNI)
August 18, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/SNDK/pressreleases/3903291/analysts-are-bullish-on-these-na-stocks-curis-cris-canadian-national-railway-cni/
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country.tc pixel
October 13 at 1:00 AM  |  Banyan Hill Publishing (Ad)
Curis Inc.’s 1-for-20 Reverse Split Raises Liquidity Concerns and Odd-Lot Trading Risks
August 16, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/curis-inc-s-1-for-20-reverse-split-raises-liquidity-concerns-and-odd-lot-trading-risks?utm_source=marketbeat.com&utm_medium=referral
Curis prices $5.6 million public offering
August 13, 2026  |  msn.comhttps://www.msn.com/en-us/money/companies/curis-prices-5-6-million-public-offering/ar-AA2a1Ha1
Curis Prices $5.6 Million Public Offering With Healthcare-Focused Institutional Investors
August 13, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/curis-prices-5-6-million-132842403.html
See More Curis Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Curis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Curis and other key companies, straight to your email.

About Curis

Curis (NASDAQ:CRIS) is a clinical-stage biotechnology company focused on developing innovative therapies for the treatment of cancer. The company’s research programs target biological pathways involved in tumor growth, survival and immune regulation, with the goal of addressing cancers that have limited treatment options.

Curis’ lead investigational product is emavusertib, also known as CA-4948, an oral inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4). The compound has been evaluated in clinical studies for hematologic malignancies, including acute myeloid leukemia and myelodysplastic syndromes, as well as certain solid tumors. As an investigational medicine, emavusertib has not been approved for general commercial use.

The company has historically used collaborations to advance its drug-development programs. Curis collaborated with Genentech on Hedgehog-pathway therapeutics, including vismodegib, which was later approved as Erivedge for certain forms of advanced basal cell carcinoma. Curis is headquartered in Lexington, Massachusetts, and its activities are primarily focused on oncology research and clinical development conducted through global partnerships and clinical-study networks.

View Curis Profile
Earnings Tools